```html

Drug Rash (Medication‑Induced Skin Reaction)

What is Drug Rash?

A drug rash is a skin eruption that occurs as an adverse reaction to a medication. It can range from a mild, localized redness to a widespread, life‑threatening eruption such as Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Most drug rashes develop within a few days to weeks after starting a new medication, but some may appear after months of therapy or even after the drug has been stopped.

Because the skin is a visible organ, a drug rash often serves as the first clue that a medication is causing a systemic problem. Recognizing the pattern, timing, and accompanying symptoms helps clinicians differentiate a benign allergic rash from a serious hypersensitivity reaction.

Common Causes

More than 100 drugs have been reported to cause cutaneous reactions. The most frequent culprits fall into the following categories:

• Antibiotics – especially β‑lactams (penicillins, cephalosporins), sulfonamides, and fluoroquinolones.
• Anticonvulsants – carbamazepine, lamotrigine, phenytoin, and phenobarbital.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen, naproxen, diclofenac.
• Allopurinol – used for gout; a leading cause of severe cutaneous adverse reactions.
• Antiretrovirals – especially nevirapine and efavirenz.
• Antibiotic‑containing topical agents – neomycin, bacitracin.
• Cardiovascular drugs – amiodarone, ACE inhibitors, and thiazide diuretics.
• Chemotherapy agents – methotrexate, cytarabine, and taxanes.
• Biologic agents – TNF‑α inhibitors (etanercept, infliximab) and interleukin blockers.
• Vaccines – rare but can trigger a rash, especially in individuals with prior drug hypersensitivity.

Genetic predisposition and previous drug allergies increase the risk. For example, HLA‑B*15:02 is linked to carbamazepine‑induced SJS in people of Asian ancestry (CDC, 2022).

Associated Symptoms

Skin findings are often accompanied by systemic signs that reflect the severity of the hypersensitivity reaction:

• Fever or chills
• Generalized itching (pruritus)
• Swelling of the face, lips, or tongue (angio‑edema)
• Joint or muscle aches
• Gastrointestinal upset – nausea, vomiting, abdominal pain
• Respiratory symptoms – cough, wheezing, shortness of breath
• Ocular involvement – redness, tearing, photophobia
• Oral mucosal lesions – painful sores or blistering inside the mouth

When a rash appears with any of the above systemic manifestations, it often signals a more serious drug reaction that requires prompt medical evaluation.

When to See a Doctor

Not every rash needs urgent care, but you should call your healthcare provider if you notice:

• The rash spreads rapidly or covers large areas of the body.
• You develop fever > 38 °C (100.4 °F) with the rash.
• Swelling of the face, lips, tongue, or throat (possible airway compromise).
• Blisters that rupture or form a “target” (bullous or erythema multiforme‑like) pattern.
• Persistent itching that interferes with sleep or daily activities.
• New onset of wheezing, shortness of breath, or chest tightness.
• Signs of organ involvement – dark urine, jaundice, severe abdominal pain.
• Any rash that appears within 24 hours of starting a high‑risk medication (e.g., allopurinol, carbamazepine, sulfonamides).

When in doubt, seek evaluation early. Early discontinuation of the offending drug can prevent progression to severe reactions.

Diagnosis

Diagnosing a drug rash involves a combination of patient history, physical examination, and sometimes specialized testing.

1. Detailed Medication History

• List every prescription, over‑the‑counter (OTC) drug, supplement, and herbal product taken in the past 8‑12 weeks.
• Note the start date, dosage, and any recent dose changes.
• Identify prior drug allergies or reactions.

2. Clinical Pattern Recognition

Clinicians categorize rashes based on appearance:

• Maculopapular exanthem – most common, flat/red spots with raised bumps.
• Urticarial (hives) – wheals that often migrate.
• Fixed drug eruption – round, dusky-red patches that recur at the same site.
• Erythema multiforme – target lesions, often on extremities.
• Severe cutaneous adverse reactions (SCARs) – SJS, TEN, drug reaction with eosinophilia and systemic symptoms (DRESS).

3. Laboratory Tests (when indicated)

• Complete blood count (CBC) – eosinophilia may suggest DRESS.
• Liver function tests (AST, ALT, bilirubin) – monitor for hepatic involvement.
• Renal panel – creatinine, BUN for kidney injury.
• Serum tryptase – elevated in anaphylaxis‑type reactions.

4. Skin Biopsy

A dermatologist may perform a punch biopsy to differentiate drug rash from infectious or autoimmune skin disease, especially for SCARs.

5. Patch or Intradermal Testing

In select cases, especially for delayed‑type reactions, allergy specialists can do skin testing to confirm the culprit drug.

Treatment Options

The cornerstone of management is identifying and stopping the offending medication. Treatment thereafter depends on rash severity.

Mild to Moderate Rashes

• Discontinue the suspected drug (often under physician guidance).
• Antihistamines – cetirizine, loratadine, or diphenhydramine for itching.
• Topical corticosteroids – low‑to‑mid potency (e.g., hydrocortisone 1% or triamcinolone 0.1%) applied 2–3 times daily.
• Cool compresses or oatmeal baths to soothe inflamed skin.
• Maintain hydration and avoid irritants (harsh soaps, tight clothing).

Severe or Extensive Reactions

• Hospital admission for SJS, TEN, DRESS, or extensive urticaria with airway involvement.
• Systemic corticosteroids – oral prednisone 0.5–1 mg/kg/day or IV methylprednisolone for rapidly progressing cases (use is controversial for SJS/TEN; refer to specialist).
• Intravenous immunoglobulin (IVIG) – sometimes employed in SJS/TEN to halt progression.
• Ciclosporin or TNF‑α inhibitors – emerging evidence for severe SCARs (Cleveland Clinic, 2023).
• Supportive care – fluid and electrolyte management, pain control, wound care similar to burn treatment for TEN.

Adjunctive Measures

• Antibiotics only if secondary bacterial infection is proven.
• Bronchodilators for wheezing or bronchospasm.
• Epinephrine auto‑injector (1 mg IM) for anaphylaxis‑type presentation (rapid onset, hypotension, airway swelling).

Prevention Tips

While not all drug rashes are predictable, several strategies help lower risk:

• Maintain an up‑to‑date medication list and share it with every provider.
• Ask about known drug allergies before new prescriptions.
• Start high‑risk medications (e.g., allopurinol, carbamazepine) at low doses and titrate slowly while monitoring.
• Consider pharmacogenetic testing when indicated (e.g., HLA‑B*15:02 for carbamazepine in Asian patients).
• Never reuse a medication that previously caused a rash without specialist clearance.
• Read medication leaflets for rash warnings; report any new skin changes promptly.
• Wear medical alert jewelry if you have a known severe drug allergy.
• Avoid self‑medication with OTC products that contain multiple active ingredients.

Emergency Warning Signs

These signs require immediate medical attention—call 911 or go to the nearest emergency department.

• Rapid spreading of redness or blistering covering more than 30% of body surface area.
• Severe mucosal involvement (eyes, mouth, genitalia) with painful erosions.
• Difficulty breathing, swallowing, or a feeling of throat tightening.
• Sudden drop in blood pressure (feeling faint, dizziness, pale skin).
• High fever (> 39 °C / 102 °F) with a rash.
• Swelling of the lips, tongue, or face (angio‑edema).
• Confusion, seizures, or altered mental status.
• Rapid onset of a rash after a known high‑risk drug (e.g., carbamazepine within days).

Key Take‑aways

• Drug rash is a common manifestation of medication hypersensitivity; early recognition can prevent serious complications.
• Most cases are mild and improve after stopping the drug and using antihistamines or topical steroids.
• Severe reactions (SJS, TEN, DRESS) are medical emergencies that need hospital‑based care.
• Keeping a thorough medication list and informing providers of past reactions are essential preventive steps.

---

References:

1. Mayo Clinic. “Drug rash.” Updated 2023. https://www.mayoclinic.org
2. U.S. Centers for Disease Control and Prevention. “Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis.” 2022. https://www.cdc.gov
3. National Institutes of Health, National Library of Medicine. “Drug Hypersensitivity.” 2024. https://pubmed.ncbi.nlm.nih.gov
4. World Health Organization. “Guidelines for the Management of Severe Cutaneous Adverse Reactions.” 2023.
5. Cleveland Clinic. “Management of Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis.” 2023.
6. Pharmacogenomics Knowledgebase (PharmGKB). “HLA‑B*15:02 and Carbamazepine‑Induced SJS.” 2022.

```